Table 2. Secondary genetic and molecular... | American Society of Hematology

Table 2.

Secondary genetic and molecular abnormalities in CML-BC

Abnormality	Patients with abnormality, %
Genetic
Double Ph¹ chromosome	38
Trisomy chromosome 8	38
i(17q)	20
Trisomy chromosome 19	13
t(3;21)(q26;q22)	2
t(7;11)(p15;p15)	< 1
Molecular
p53 mutations	25-30^*
p16/ARF mutations	50†
Rb mutation/deletion	18‡
RAS mutation	Rare

Abnormality	Patients with abnormality, %
Genetic
Double Ph¹ chromosome	38
Trisomy chromosome 8	38
i(17q)	20
Trisomy chromosome 19	13
t(3;21)(q26;q22)	2
t(7;11)(p15;p15)	< 1
Molecular
p53 mutations	25-30^*
p16/ARF mutations	50†
Rb mutation/deletion	18‡
RAS mutation	Rare

Abnormalities to watch in the post-imatinib mesylate era include BCR/ABL mutations and BCR/ABL amplifications.

Occurred in 30% of myeloid blas crisis cases

Occurred in 50% of lymphoid blast crisis cases

Occurred in 18% of lymphoid blast crisis cases